JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Response

Acute myeloid leukemia (AML) is a heterogenous disease affecting essentially patients older than 55. Although most patients experience complete remission after intensive chemotherapy, the disease remains of dismal prognosis with long-term overall survival (OS) below 40% ([1][1]). Therefore, there is